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Abstract: In the last decade, both regenerative medicine and nanotechnology have been 
broadly developed leading important advances in biomedical research as well as in clinical 
practice. The manipulation on the molecular level and the use of several functionalized 
nanoscaled materials has application in various fields of regenerative medicine including 
tissue engineering, cell therapy, diagnosis and drug and gene delivery. The themes covered 
in  this  review  include  nanoparticle  systems  for  tracking  transplanted  stem  cells,  
self-assembling peptides, nanoparticles for gene delivery into stem cells and biomimetic 
scaffolds useful for 2D and 3D tissue cell cultures, transplantation and clinical application. 
Keywords: regenerative medicine; nanomaterials; scaffolds; cell therapy; stem cells; bone; 
cartilage; cell encapsulation; cell tracking; gene and drug delivery 
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1. Introduction  
Regenerative medicine is a broad interdisciplinary science that attempts to restore lost, damaged, or 
aging cells and tissues to a state as close as possible to its native architecture and function. Therapeutic 
approaches in regenerative medicine may be divided into: (i) cell-based; (ii) biomaterials-based or  
(iii) combined tissue engineering strategies. Over the past twenty years, there have been tremendous 
advances in the fields of stem cell biology, nanotechnology and bioengineering, the intersection of which 
offers increasing potential to achieve the goal of truly regenerative therapies for myriad pathologies.  
Stem cells are defined by their ability to retain their stem cell capacity through controlled proliferation 
(self-renewal) while also dividing to produce differentiated daughter cells, which lose some degree of 
―stemness‖ and proceed to form mature cells of all lineages in the body [1]. These important functional 
properties  of  SCs,  which  are  critical  to  maintaining  organ  homeostasis,  underlie  the  tremendous 
therapeutic potential for SCs to effect tissue and organ regeneration. Stem cells are classified based on 
their source tissue and their potency, which refers to the potential of a given stem cell to differentiate 
into mature progeny by the goal of reconstructing, repairing, or replacing missing or damaged tissue [2].  
Nanotechnology is defined by the size of a material (generally 1–100 nm) or manipulation on the 
molecular  level,  and  it  involves  a  broad  range  of  nanoscaled  materials  used  in  various  fields  of 
regenerative medicine, including tissue engineering, cell therapy, diagnosis and drug and gene delivery. 
Moreover, the growing interest and expansion in nanomedicine during the last years has led to new 
perspectives and advances in biomedical research as well as in clinical practice. To date, nearly 30 
nanotechnology-based products have been approved for clinical use, focused mainly on liposomal 
formulations  and stealth polymer-drug conjugates.  The application  of nanotechnology tools  to  the 
development of structures at the molecular level enables the improvement of the interactions between 
material  surfaces  and  biological  entities.  Thus,  nanomedicine  provide  the  possibility  to  produce 
surfaces, structures and materials that can mimic the natural environment of cells, to promote certain 
functions, such as cell adhesion, cell mobility and cell differentiation [3]. 
Since Langer and Vacanti in 1993 [4] proposed the combined use of stem cells, scaffolds, and 
inductive factors as the basis for tissue engineering, researchers have been able to fabricate increasingly 
complex tissue/organ constructs and some are used clinically today as standard treatment for a variety 
of conditions. Scaffolds are processed in order to produce 3D structures, with proper shape, size, 
architecture, and physical properties, tailored to fulfil specific functions. Therefore, tissue engineering 
products are designed to mimic tissue architecture and responses. So, key scaffold requirements are 
biocompatibility, controlled porosity and permeability, suitable mechanical and degradation kinetics 
properties  comparable  to  the  targeted  tissue  and,  additionally,  support  for  cell  attachment  and 
proliferation by the addition of nanotopographies to the biomaterial surface [5,6].  
Natural or synthetic materials are used to make scaffolds and depending on the final purpose, barriers 
(membrane or tubes), gels or 3D matrices are developed to mimic the extracellular environment of a 
target tissue or organ. Natural materials are derived from human or animal (xenogeneic) sources and 
are composed of extracellular components [7]. They include collagen, silk protein, Matrigel, small 
intestinal submucosa, agarose, alginate and chitosan [8–11]. Examples of natural scaffolds that have 
been applied clinically include decellularized dermis to treat burn injuries [12] and decellularized small 
intestine ureter, or xenogeneic vessels to restore vascular function [13]. Although these materials have Int. J. Mol. Sci. 2012, 13 
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shown promising results in tissue repair, they have some drawbacks regarding mechanical properties, 
degradation,  immunogenicity  and  cross-contamination.  Synthetic  scaffolds  have  been  constructed 
using synthetic materials or a combination between natural and synthetic materials. Polyhydroxic acids, 
polytetrafluoroethylene,  steel  titanium,  or  ceramics  are  examples  of  synthetic  polymers  
with  improved  biocompatibility  [14,15].  Natural  materials,  such  as  collagen,  gelatine,  chitosan, 
alginates  and  silk  or  synthetic  poly(lactic  acid)  (PLA),  poly(lactic-co-glycolic  acid)  (PLGA),  
poly-epsiloncaprolactone (PCL), or polyvinyl alcohol (PVA) polymers, are the most common materials 
employed for the fabrication of nanofibre scaffolds. These matrices can be created with high structural 
precision, using complex polymers and assembly techniques, to control material properties such as 
stiffness, degradation and porosity. The advent of nanotechnology has allowed further developments in 
the field of biomaterials. Suitable nano-modified surfaces create a nanotopography which facilitates 
cell adhesion and can induce a better cellular response and specific cell differentiation than untreated 
surfaces [16]. For example, nano-structured PLGA surfaces have been shown to accelerate chondrocyte 
adhesion and proliferation, as well as extracellular matrix production [17,18]. Furthermore, vascular 
graft (PLGA) and stent (titanium) surfaces with nanometer surface roughness improve endothelial cell 
functions as compared to nano-smooth polymer and titanium surfaces [19,20].  
Another  promising  strategy  for  tissue  regeneration  is  the  use  of  nanomaterials  as  cell  delivery 
vehicles. The most commonly used nanomaterials are peptide amphiphiles, self-assembled peptides, 
carbon nanotubes (CNTs), electrospun fibers and layer-by-layer structures [21]. The development of 
novel nanostructures formed by bioactive molecules that can interact specifically and reproducibly 
with  cell  receptors  and  proteins  to  control  processes  such  as  cell  survival,  cell  proliferation,  cell 
differentiation, and dedifferentiation in  the context of tissue and organ regeneration has  generated 
enormous interest. Many research groups are currently taking advantage of the better understanding of 
molecular  self-assembly  and  nanoscience  to  develop  bioactive,  biomimetic,  and  multifunctional 
materials  for  regenerative medicine  [22–25]. One advantage of  functionalizing nanomaterials  over 
materials  in  general  is  the  fact  that  the  functionalization  could  be  performed  at  the  level  of  the 
nanostructural unit, to be amplified in a predictable manner as the material is built up via a bottom-up 
approach.  Later  advances  in  this  field  is  the  generation  of  bioactive  and  biodegradable  nanoscale 
filaments  that  mimic  those  in  extracellular  matrices  and  can  display  in  tuneable  densities  peptide 
signals that promote regenerative processes [26–29]. 
Controlled release of biomolecules is crucial in the support and enhancement of tissue growth in 
tissue  engineering  applications.  Nanotechnology  approaches  in  delivery  systems  can  enhance  the 
success of specific therapeutic agents, such as growth factors, proteins, peptides, DNA, RNAi and 
small drugs, which are of vital importance for tissue regeneration [30].  
Further progress in cell therapy leading to clinical trials requires the crucial use of non-invasive 
techniques  for  monitoring  the  efficacy  of  cell  therapy  and  graft  survival  in  the  host  organism.  
For pre-clinical and clinical trials, it will be important to track SCs noninvasively in order to evaluate 
their therapeutic effect and grafting location to rule out potentially dangerous side effects. Moreover, 
nanoparticle  (NP)-labeled  SCs/progenitor  cells  might  contribute  to  our  understanding  of  the  cell 
migration  processes  in  numerous  diseases,  such  as  neurologic  diseases,  myocardial  infarction  and 
cancer  [31].  In  addition,  this  platform  might  give  us  important  information  and  cues  about  the 
differentiation program of SCs. NP systems for tracking transplanted SCs have been developed using a Int. J. Mol. Sci. 2012, 13 
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variety of non-invasive imaging techniques including optical imaging (luminescence, photoacoustic 
tomography and optical coherence tomography) [32,33], magnetic resonance imaging (MRI) [34,35] 
and radionuclide imaging (PET and SPECT) [36–38].  
The aim of this review is to highlight some of the most recent advances in the exciting fields of 
nanotechnology and regenerative medicine. We will focus in the functionalization of nanostructured 
biomaterials with potential applications in regenerating different tissues. Therefore, the themes covered 
in this article include: (i) nano- or micro-fabricated scaffolds with different biomolecules (depending 
on the targeted cells) and nano-modified surfaces; (ii) stem cell encapsulation with nano-fabrication 
techniques;  (iii)  NP  systems  for  tracking  transplanted  SCs  using  several  imaging  modalities;  and  
(iv) NPs for gene and drug delivery targeting SCs. We also emphasize some of the ways they are being 
used in translational and clinical practice.  
2. Nanostructure Scaffolds for Tissue Engineering 
A main strategy of regenerative medicine is the construction of a biocompatible scaffold that, in 
combination with living cells and/or bioactive molecules, replaces, regenerates or repairs damaged 
cells or tissue. Numerous studies, using nanostructured materials, have demonstrated the validity of 
this approach for a variety of cell types and the application in regenerating different tissues (such as 
cardiac, bone, cartilage, skin, bladder, nervous and vascular) by enhancing the biological properties of 
the cells such as cell adhesion, cell mobility and cell differentiation [3,39–42]. In the in vivo condition 
the cells are located in three-dimensional (3D) microenvironments, where they are surrounded by other 
cells and by the extracellular matrix (ECM), whose components, such as collagen, elastin, and laminin, 
are organized in nanostructures (i.e., fibers, triple helixes, etc.) with specific bioactive motifs that 
regulate  the  cell  homeostasis.  It  is  therefore  essential  to  develop  scaffolds  that  create  synthetic 
microenvironments providing 3D support, so as to control  and direct the cellular behavior and to 
promote specific cell interactions [43,44]. The goal of nanomaterial-directed stem cell culture is to 
mimic  the  properties,  both  physical  and  biochemical,  of  the  physiological  stem  cell  niche. 
Electrospinning is a widely used technique for the production of nanofibers that offers great flexibility 
in terms of the choice of scaffold material, as well as finer control over the scaffold geometry [45–47]. 
In the electrospinning process, nanofibres are created as polymeric jets from the surface of a polymeric 
solution in a high intensity electrostatic field when the electric field overcomes the polymer surface 
tension. Modulation of spinning parameters such as flow rate and collecting distance, and polymer 
solution properties such as solvent, concentration, conductivity, and surface tension, properties of the 
resultant  nanofibrous  meshes,  such  as  fibre  diameter,  porosity,  mechanical  properties  and  surface 
topography can be easily controlled [48,49]. Moreover, additional functionalities can be incorporated 
via protein coatings, or chemical conjugation of specific  signalling molecules with great utility in  
SCs-based therapy [50]. The development of these nanoscaffold-based therapy methods in combination 
with SCs is an important tool for tissue engineering and regenerative medicine.  
2.1. Nanoscaffolds Used in Regeneration of Hard Tissues 
The ideal situation for hard tissue regeneration is to utilize ―bioactive‖ materials that stimulate 
active tissue regeneration. Substrate rigidity or flexibility has been shown to regulate cell behaviour Int. J. Mol. Sci. 2012, 13 
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and is a critical determinant of tissue function [51]. Stiffer scaffolds are generally more suitable for 
load-bearing bone or cartilage engineering.  
2.1.1. Bone Regeneration 
The bone tissue is a mineralized organic matrix mostly formed from collagenous fibres and calcium 
phosphate in the form of hydroxyapatite (HA), with embedded osteoblasts, osteocytes and osteoclasts 
as cell components. For bone reconstruction, nanoscaffolds have been provided with suitable biophysical 
properties, such as hardness and porosity, as well as support for cell growth and differentiation. In the 
past several years, various nanofibrous matrices have been created. Most of the nanoscaffolds produced 
emulate the structural, compositional and biological characteristics of natural bone. They are based 
primarily on nano-HA, collagen, electro-spun silk, anodized titanium and nano-structured titanium 
surfaces [52–55]. Nanofibres have been shown to promote osteogenesis and biomineralization with 
primary osteoblasts [56–58]; however, the use of primary osteoblasts is limited by (i) the restricted 
availability and inherent donor site morbidity; (ii) their limited proliferative capacity; (iii) the age 
dependent behavior; or (iv) the risk of dedifferentiation during in vitro culture.  
On the other hand, SCs are an attractive option because their large proliferative capacity and their 
ability to differentiate into multiple cell types [59]. Numerous studies have illustrated the ability of 
mesenchymal stem cells (MSCs) collected from several sources to differentiate into osteoblasts under 
osteogenic conditions on nanofibres. For instance, bone marrow-derived MSCs posses the ability to 
differentiate into bone tissue after seeding on natural (collagen or silk fibroin), degradable synthetic 
polymers (PLA, PCL and PLGA) as well as on a blend of synthetic and natural polymers such as 
gelatine,  collagen,  silk  fibroin  and  chitosan  [60–62].  In  another  study,  a  combination  of  bone 
morphogenic protein 2 (BMP-2) and HA NPs encapsulated into silk electrospun matrices was used to 
synergistically enhance bone formation from seeded bone marrow-derived human MSCs (hMSCs) [63]. 
Recently  it  has  been  shown  the  effects  of  functionalized  nano-HA,  PLGA,  or  nano-HA-PLGA 
composites, and a bone morphogenetic protein (BMP-7)-derived short peptide (DIF-7c) on osteogenic 
differentiation of bone marrow-derived hMSCs. Results showed that nano-HA and nano-HA-PLGA 
composites  promoted  an  osteogenic  differentiation  of  hMSCs,  comparable  with  the  differentiation 
obtained by direct injection of the DIF-7c peptide into the culture media. These findings could be 
eventually translated to clinical applications [64].  
Other promising materials for bioengineering applications are carbon nanotubes (CNTs). CNTs are 
conductive and have nanostructured dimensions that mimic the 3D structure of proteins found in ECM. 
Large  CNTs  lead  to  a  dramatic  stem  cell  elongation,  inducing  cytoskeletal  stress  and  selective 
differentiation into osteoblast-like cells [65]. Furthermore, hMSCs grown on CNTs networks could 
recognize the arrangement of individual CNTs in the CNT network. Namgung  et al. showed that 
hMSCs on aligned CNTs networks exhibited enhanced proliferation and osteogenic differentiation 
compared  to  those  on  randomly  oriented  CNT  networks  due  to  mechanotransduction  pathways 
triggered by high cytoskeletal tension in the aligned hMSCs [66]. In addition, surface engineering in 
carbon  nanoscaffold  such  as  carbon-coated  TiO(2)  nanotubes  or  functionalized  PEG-conjugated 
multiwalled carbon nanotubes (MWCNT-PEG) sprayed onto plain coverslips induced higher levels of 
osteo-differentiation in hMSCs [67,68]. Engineering graphene consists in a two-dimensional structure Int. J. Mol. Sci. 2012, 13 
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comprising layers of carbon atoms arranged in six-membered rings [69], and might be a novel option 
for bone tissue regeneration.. Results have shown that proliferation and morphology of hMSCs were 
not affected after seeded on graphene films. Moreover in presence of an osteogenic medium, graphene 
coating  helped  by  remarkably  accelerating  the  differentiation  of  hMSCs  at  a  rate  comparable  to 
differentiation under the influence of BMP-2 [70]. Lee et al. have suggested that the rapid osteogenic 
differentiation could be due to the ability of graphene to act as a platform for the accumulation and 
interactions of osteogenic inducers included in the conditioned medium such as dexamethasone and  
β-glycerolphosphate  [71].  Specific  interactions  with  other  inducers  (e.g.,  insulin)  can  block 
differentiation into other cell types. Moreover, some of these properties might be altered by varying the 
composition of graphene; for example, graphene oxide does not alter the structure of insulin and cells 
can differentiate into adipose tissue [71]. 
In two recent studies Seyedjafari et al. seeded HA and nano-HA coated and uncoated electrospun 
PLLA fibres with human cord blood derived SCs and implanted the scaffolds subcutaneously into  
mice [72,73]. After 10 weeks, scaffolds without HA showed no calcium deposition and were surrounded 
by a granulomatous inflammatory response while scaffolds with HA showed significant mineralization 
with little inflammatory response [72]. Additionally, higher order bone structures such as trabeculi and 
bone marrow were found within the newly formed ectopic bone [72,73].  
Nanofibrous (NF) matrices have also been shown to enhance the expression of osteogenic genes 
and proteins and calcium staining of pluripotent embryonic stem cells (ESCs) [74]. Recently, Smith et al. 
examined the effects of the nanofibrous architecture in both two-dimensional (2-D) PLLA thin matrices 
and 3D PLA scaffolds to assess their effect on the osteogenic differentiation of human ESCs (hESCs) 
in vitro compared to more traditional solid films and solid-walled (SW) scaffolds. After 6 weeks of 3D 
culture, the hESCs on the NF scaffolds expressed significantly more osteocalcin mRNA compared to 
these  on  the  SW  scaffolds.  The  data  indicates  that  the  NF  architecture  enhances  the  osteogenic 
differentiation  of  the  hESCs  compared  to  more  traditional  scaffolding  design  [75].  In  addition, 
homogenous hESCs-derived MSCs (hESCs-MSCs) have been generated and used to construct bone 
tissue. The hESCs-MSCs cultured on 3D NF PLLA scaffolds in combination with dexamethasone and 
BMP-7 stimulation in vitro showed highly mineralized tissues developed with specific bone marker 
genes expressed. These results indicate the promise of hESCs-MSCs for bone regeneration [76].  
Reprogramming  somatic  cells  into  an  ESC-like  state,  induced  pluripotent  stem  (iPS)  cells,  has 
emerged  as  a  promising  new  venue  for  customized  cell  therapies  that  avoided  the  controversy 
surrounding human ESCs. A recent study demonstrated the ability of murine iPS-derived osteoblasts 
seeded in a gelfoam matrix followed by subcutaneous implantation, in syngenic imprinting control 
region mice, to express matrices characteristic of bone [77]. Moreover, graphene and graphene oxide 
have  the  ability  to  act  as  platforms  to  support  the  iPSCs  culture,  exhibiting  disparities  in  the 
differentiation propensity. Graphene hampered  spontaneous  differentiation towards the endodermal 
lineage whereas graphene oxide promoted differentiation along the endodermal pathway. These results 
underlined that the different surface properties of graphene and graphene oxide governed the iPSCs 
behavior, which have great potentials for regenerative medicine [78]. Int. J. Mol. Sci. 2012, 13 
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2.1.2. Cartilage Regeneration 
Cartilage is an avascular tissue composed of chondrocytes entrapped in an ECM rich in proteoglycans 
and collagens. Chondral defects suppose a challenging clinical problem as the proportion of elderly 
people in the population increase. Cartilage injuries lead to joint pain and loss of function with limited 
capacity for self-repair [79]. Innate repair mechanisms in cartilage are limited due to the scarcity/absence 
of resident SCs and the lack of a vascular and lymphatic system. Clinical treatments for articular 
cartilage injury include physical therapy, arthroscopic drilling, debridement, autologous osteochondral 
grafts from non-weight-bearing body regions, or autologous cell injections. However, the donor site 
morbidity  and  the  difficulty  in  trimming  and  grafting  for  the  desired  shape  limit  their  clinical 
applications [80].  
Tissue engineering strategies have long been used for cartilage regeneration and have been based 
mostly on matrix seeded with either chondrocytes or MSCs [81]. Biomaterials, for instance, collagen, 
fibrin, alginate, chitosan, hyaluronic acid and polyesters have been employed into 3D exogenous ECMs 
for guiding cartilage regeneration [82]. NF scaffolds have introduced some advantages, such as high 
surface area, volume ratio and collagen fibre-mimetic nano-scale fibres, which can be translated into 
biologically favourable properties to enhance cartilage growth [83]. A recent study shows an increased 
chondrogenic differentiation and the production of ECM of BM-derived hMSCs seeded on electrospun 
PCL nanofiber meshes and cultured in a multichamber flow perfusion bioreactor [84].  
The applicability of stem cell-seeded on NF scaffolds has also been evaluated in vivo. The capacity 
of cartilage regeneration of BM-derived hMSCs on PVA/PCL nanofibre scaffolds has been assayed 
after  implantation  into  rabbit  full-thickness  cartilage.  To  improve  the  surface  hydrophilicity,  the 
biocompatible water-soluble synthetic biodegradable polymer PVA was selected to  be electrospun 
concurrently with PCL via hybrid electrospinning. Results showed that PVA/PCL scaffolds supported 
the proliferation and chondrogenic differentiation of MSCs in vitro and when cell-seeded PVA/PCL 
scaffolds  were  implanted  the  animals  treated  showed  improved  healing  of  defects  compared  with 
untreated control and those which received cell-free scaffolds [85]. Combination of hydrogels and NPs 
containing a specific grow factor represents a suitable niche for the differentiation of transplanted 
hMSCs. hMSCs grown into hydrogels with NPs bearing TGF-β3 produced cartilage-specific ECM 
proteins such as collagen type II and glycosaminoglycan. The expression of these chondrocyte-specific 
ECM proteins clearly showed that hMSCs chondrogenesis occurred when the SCs were mixed with 
growth factor. Transplanted hMSCs into nude mice and rabbits arthritis defects proliferated easily and 
reliably, and switched without difficulty into differentiated chondrocytes capable of regenerating the 
wound  tissue  and  finally  remodelling  the  wound  sites  in  the  animals.  These  results  showed  that 
combined (cell and protein) delivery system helped to increase transplanted stem cell differentiation, 
thereby stimulating regeneration cascade events both in vitro and in vivo [86]. Another in vivo study 
was conducted in a swine model, and showed the applicability of biodegradable PCL NF scaffold, in 
this case, seeded with allogeneic chondrocytes or xenogeneic hMSCs. Thus, NF scaffolds effectively 
deliver therapeutic cells to cartilage lesions and support chondrogenic activity during the cartilage 
regeneration in vivo. The xenogeneic hMSCs-based treatment proved to repair cartilage defects and 
restore biomechanical functions of cartilage, suggesting the potential of MSCs xeno- or allo-grafting 
for cartilage tissue engineering [87].  Int. J. Mol. Sci. 2012, 13 
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3. Cell Encapsulation: Use in Regenerative Medicine 
Cells in native tissue are embedded within a complex 3D microenvironment consisting of soluble 
molecules (cytokines and growth factors) and non-soluble factors (mainly ECM). The microenvironment 
not only provides structural integrity, but also controls numerous signal transduction processes that 
direct  cell  survival,  cell  cycle  progression,  and  the  expression  of  different  phenotypes  [88].  Cell 
encapsulation technology is based on the immobilization of cells within a semi-permeable membrane 
(Figure 1). This membrane protects the inner cells from both mechanical stress and the host immune 
system, while allowing the bidirectional diffusion of nutrients, oxygen and waste [89]. About 50 years 
ago, Chang proposed the protection of proteins and cells, by encapsulating them in a semi-permeable 
membrane [90]. Twenty years later, Lim and Sun presented the first implantable alginate-poly(L-lysine) 
microcapsules harbouring rat islet cells, that naturally secreted insulin, for the treatment of diabetes [91]. 
This was the first proof-of-principle study demonstrating the applicability of encapsulated cells.  
Figure  1.  Schematic  illustration  of  cell  encapsulation  technology.  The  semi-permeable 
membrane allows the bidirectional diffusion of nutrients, oxygen, therapeutic products and 
waste. At the same time this membrane avoids the entrance of immune cells and antibodies. 
 
The  cellular  recognition  of  biomaterials  and  the  progression  of  subsequent  cellular  events  are 
essentially based on integrin-mediated interactions, but depend in particular on the chemical and physical 
characteristics  of  biomaterials.  The  micro-fabricated  biomaterials  offer  several  advantages:  (i)  the 
individual parts of living cells exist in nano- or micro-scale lengths, and thus micro- or nano-fabrication 
techniques enable the recapitulation of their features; (ii) the micro-fabricated substrate can present 
simultaneously multiple adhesive or morphogenic signals in a small dimension simultaneously; and (iii) 
multiple parameters governing cell-biomaterial interactions could be analyzed separately with a small 
amount  of  analytes  [92].  Microcapsule  design  must  take  into  account  a  series  of  consideration 
including material biocompatibility, mechanical stability, permeability, size and durability. One main 
concern is the biocompatibility of the materials used, it should not interfere with cell homeostasis 
(encapsulated cells and surrounding host tissue) nor trigger an immune response in the host  [93].  Int. J. Mol. Sci. 2012, 13 
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An interesting advance to predict biocompatibility was reported by de Vos et al., where the measurement 
of the surface electrical charge, by means of zeta potential, was found to predict the interfacial reactions 
between the biomaterial and the surrounding tissue [94]. Mechanical stability must be maintained, 
because microcapsules withstand physical and osmotic stress and its breakage may lead to immune 
rejection of the encapsulated cells. Moreover, the capsule must have adjusted permeability in terms of 
entry and exit of the molecules. To gain a tight control of transport properties, it is essential that 
membrane wall thickness is uniform. The thinner the membrane, the faster is the nutrient diffusion and 
lower is the implant volume.  
Another main concern is the immunoreactions against the capsule, which probability will trigger the 
immune system of the body. So encapsulated cells should be immunoprotected not only from immune 
cells but also from antibodies and cytokines [93]. An interesting approach using agarose capsules of 
different diameter developed by Sakai et al. revealed that cellular reaction to the smaller capsules was 
much  lower  than  that  to  the  larger  capsules  [95].  Thus,  reduction  in  capsule  diameter  not  only 
increased  mechanical  stability  but  also  decrease  the  immune  response  against  capsules.  To  fulfill  
the  therapeutic  goal  of  encapsulation,  the  biomaterial  degradation  rate  should  provide  a  sustained 
release of substances over a long period of time, into the surrounding environment, in a controlled 
fashion [93,96]. Other important issue is the technique used for encapsulation, because this process 
must  be  gentle  and  preserve  cell  integrity  (i.e.,  aqueous  medium,  no  reactive  species,  no  organic 
solvent). It is important to choose a reproducible method in which different parameter can be tightly 
controlled, for instance, permeability, size, and surface area. So far, different methods have been used 
to  prepare cell-loaded microcapsules,  including  extrusion (electrostatic spray, air flow nozzle, and 
vibrating nozzle), emulsion/thermal gelation (agarose as core polymer), and microfluidic flow focusing 
approach [93,97,98]. 
The  first  assays  of  encapsulation  were  made  using  matrix-core/shell  microcapsules.  Cells  were 
embedded  in  hydrogel  matrix,  often  surface-modified  by  one  or  more  external  layers  of  different 
materials to improve permeability and stability properties, preventing cell release from the beads and 
ensuring biocompatibility (Figure 2). Despite that the hydrogels matrix allowed cell grown, the in vivo 
stability of electrostatic and hydrogen bonds maintaining the structure of microcapsules is limited, and 
the mechanical resistance of capsules is still a concern. Liquid-core/shell microcapsules where cells are 
embedded in liquid seem to allow better cell growth and protein production, because diffusion of gases 
and nutrients is higher in liquid than in gel, although their mechanical resistance is further diminished 
compared to matrix-core capsules. In this respect, semi-liquid cores and cells-core/shell where cells are 
directly  surrounded  by  a  coating  layer  appear  to  be  good  options.  However,  several  questions 
pertaining to mechanical resistance (related to strength of the cell aggregates), the consequences of cell 
growth and death on the integrity of the immunoisolation barrier, and finally, long-term stability and 
performance, need to be addressed [93,97]. Figure 2 shows a schematic vision of the different models 
of encapsulations described here. Int. J. Mol. Sci. 2012, 13 
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Figure  2.  Models  of  cell  encapsulation.  (a)  Matrix-core/shell  microcapsules;  
(b) Liquid-core/shell microcapsules; (c) Cells-core/shell microcapsules.  
 
Alginate  is  the  most  common  encapsulation  material  due  to  its  intrinsic  properties  including 
biocompatibility, biosafety and permeability. The production of alginate cell microcapsules can be 
performed under safe and physiological conditions (e.g., physiological temperature and pH, use of 
isotonic  solutions  instead  of  cytotoxic  solvents)  and  using  good  manufacturing  practice  (GMP) 
guidelines, a fact which potentiates the use of this technology in cell-based therapies [99–101]. Recently, 
Serra et al. evaluated benefits of microencapsulation in alginate when performing cell cultures. This 
work  established  that  microencapsulation  technology  may  be  a  powerful  tool  for  integrating  the 
expansion  and  cryopreservation  of  pluripotent  hESCs.  The  3D  culture  strategy  developed  herein 
represents a significant breakthrough towards the implementation of hESCs in clinical and industrial 
applications [99]. The potential of alginate microcapsules for transplantation is actually being tested, 
with two clinical trials currently under development using this material. One Phase I study is based on 
the encapsulation and transplantation of human islets in Type I diabetic patients (ClinicalTrials.gov 
Identifier: NCT00790257). And in the other, a Phase II clinical trial, the transplant is performed with 
encapsulated β cells for patients with Type I diabetes (ClinicalTrials.gov Identifier: NCT01379729). 
Table 1 shows the most frequently used materials in cell encapsulation for several diseases.  
Table 1. Compilation of different materials used in encapsulation according to the disease 
for which they are intended. PEG (poly ethylene glycol); PLO (poly  L-ornithine); PLL 
(poly L-lysine); PVA (poly vinyl alcohol); PLGA (poly L-lactide-co-glycolide). 
DISEASES  MEMBRANE MATERIAL  Ref. 
DIABETES  Alginate  [102] 
  Alginate-PEG  [103] 
  Alginate-PLO  [104,105] 
  Alginate-PLL  [104] 
  Alginate-Chitosan  [105,106] 
  PVA  [107] 
  Agarose  [108] 
LIVER FAILURE  Alginate-Chitosan  [109] 
  PEG  [110] 
  PLL  [111] Int. J. Mol. Sci. 2012, 13 
 
 
3857 
Table 1. Cont. 
CARDIOVASCULAR DISEASE  Alginate  [112] 
  Fibrin  [113] 
 
Alginate-PLL 
Alginate-Chitosan 
[96] 
[114] 
CNS DISEASE  Alginate-PLL  [115] 
  PVA  [116] 
  PLL-PLGA  [117] 
BONE TISSUE ENGINEERING  Collagen  [118] 
  Alginate-Chitosan  [119] 
  Agarose-PEG  [120] 
  Carboxymethyl xanthan  [121] 
  Chondroitin sulfate-Agarose-PEG  [122] 
CANCER  Alginate-PLL  [123] 
  Hyaluronic acid  [124] 
  Agarose  [125] 
  Theracyte  [126] 
  APA  [127] 
At the present, many studies focus on the encapsulation of SCs as a starting point for regenerative 
medicine,  engineering  tissue  and  gene  therapy  [98].  Therefore,  the  main  objective  of  stem  cell 
microencapsulation technology is to maintain the undifferentiated state of the cells and the controlled 
differentiation  with  the desired  functions  of  those  cells.  Although  the most  employed  material  to 
develop  the  capsules  is  alginate,  however,  it  has  been  reported  that  a  novel  microencapsul ation 
technique fabricating self-assembled collagen—MSCs microspheres can be used as delivery devices 
for MSCs [128].  
In summary, cell encapsulation allows continuous delivery of products from the cells for a longer 
period of time and, also, the transplantation of non-human cells, which could be considered as an 
alternative to the limited supply of autologous tissue. In addition, genetically modified cells can be 
immobilized to express any desired protein in vivo without the modification of the host genome [89,129] 
and achieve a transplant without immunosupression for the patients [97,130]. Nevertheless, successful 
application  of  microencapsulation  requires  interdisciplinary  expertise  ranging  from  biomedicine  to 
materials science. Based on all the above, it has been proposed that layer by layer nanoscale coatings 
can  be  applied  directly  to  the  surface  of  the  cell(s)  to  be  encapsulated  instead  of  using 
microencapsulation  technology.  These  biocompatible  nano-structured  coatings  serve  in  a  similar 
fashion  as  the  micro-capsules  but  have  the  advantage  of  easy  diffusion  of  oxygen  and  essential 
nutrients. The encapsulation using nanotechnology also significantly reduces the volume of cells to be 
encapsulated [131,132].  
4. Nanoparticle Systems for Tracking Transplanted SCs 
The therapeutic potential of SCs in illnesses such as myocardial infarction, stroke, regeneration of 
bone and cartilage defects, spinal cord injury, graft-versus-host disease and blood disorders is widely 
recognized. In addition these cells are useful tools for modelling a broad range of diseases, both in vivo Int. J. Mol. Sci. 2012, 13 
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animal and in vitro. Among the intrinsic characteristic of SCs, their immunomodulatory properties and 
their low immunogenicity are essential features to be  ideal candidates  for cell therapy treatments. 
Adult MSCs have been shown to generate a local immunosuppressive microenvironment via cytokines 
activity and could produce key factors to inhibit both fibrotic and apoptotic phenomena [133]. 
Assuming that SCs may not trigger the immune response it is still important to consider how these 
cells can be guided to specific locations once they are transplanted into the patient. To monitor and 
evaluate the engraftment in the host, cells are labelled ex vivo to distinguish the implanted cells from 
the host tissue cells and follow their survival, migration, differentiation and regenerative impact in 
living subjects [134]. 
In these terms NP technology could help to track and localize transplanted cells. Nanocapsules are 
made with unique optical and/or magnetic properties to allow a non-invasive, accurate and real-time 
cell tracking [135]. Ideally, imaging technology used for SC tracking would have single-cell sensitivity 
allowing quantification of exact cell numbers at any anatomic location. In vivo imaging requires that a 
contrast agent associated with the transplanted cells exert an ―effect size‖ sufficient for detection by 
the imaging hardware. Fluorescence labelling techniques are not sensitive enough to track  in vivo 
injected cells because this approach requires invasive methods in order to address location of labelled 
cells [136]. For in vitro studies, microscopic optical imaging techniques include light and fluorescence 
microscopy, confocal microscopy, and two photon microscopy. 
Conventional technologies and new approaches in the clinical radiology field have been used to 
track injected cells in vivo. X-ray, ultrasound and computed tomography (CT) have the disadvantage to 
require high concentrations of high density, high atomic number materials such as iodine, gadolinium, 
or metals, in order to achieve good contrast for image acquisition. Multimodality imaging techniques 
such as CT/positron emission tomography (PET), CT/single-photon emission computed tomography 
(SPECT),  and  magnetic  resonance  imaging  (MRI)/PET  combine  different  ―anatomical‖  and 
―functional‖ methods. In this regard, MRI provides a very safe method for human in vivo imaging 
using a powerful magnetic field to align the nuclear magnetization of hydrogen atoms, which are 
responsible  for  the  majority  of  MRI  signals  [137,138].  However,  issues  regarding  to  optimal 
concentration of image labelling agents and NP volume need to be studied, in order to improve the 
sensitivity and decrease background noise of the tracking methods.  
4.1. Superparamagnetic Iron Oxide Particles (SPIO) 
Combination of NPs and MRI are currently used for biomedical applications, however, contrasts 
agents  used  are  mostly  iron  particles  which  accumulate  in  the  liver.  To  improve  imaging  probes 
sensitivity and decrease particle toxicity, new strategies to coat the iron particles have been developed, 
consisting  of  nonstoichiometric  microcrystalline  magnetite  cores,  which  are  coated  with  dextrans  
(in ferumoxide) or siloxanes (in ferumoxsil). These SPIO are now used as MRI contrast probes for 
studying the fate of transplanted cells [139]. Commercially available dextran-coated SPIO (4.8–5.6 nm) 
ferumoxide  NPs  have  been  approved  as  intravenous  contrast  agents  by  the  U.S.  Food  and  Drug 
Administration (FDA) as Feridex
® and Endorem
® or as ultrasmall NPs (Combidex
®, Sinerem
®). Coating 
SPIO NPs with a protective layer of dextran or other polysaccharide helps to prevent their aggregation, Int. J. Mol. Sci. 2012, 13 
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induces the efficient internalization of the contrast agent into the cell and minimizes any deleterious 
effects on cellular function [140]. 
In summary, these novel contrast agents present the advantages of suitable magnetic saturation, 
superparamagnetic  properties,  and  also  their  colloidal  stability  and  biocompatibility  [141,142].  
In addition, they present less toxicity and do not adversely affect on cell physiology, differentiation, or 
cell migration.  
4.1.1. SPIO Integration into SCs 
Figure  3.  Scheme  showing  an  overview  of  stem  cell  tracking:  a  work  flow  chart  for 
labelling cells and introducing labelled cells into the human body include: (1) SPIO NPs 
are taken into the cell by an endocytosis process. This requires the coordinated action of 
some proteins like ENTH domain containing proteins, BAR superfamily proteins, ARF 
family small G proteins, proteins that nucleate actin polymerization, and dynamin superfamily 
proteins. The best-understood mechanism is clathrin-mediated endocytosis (CME). (2) Cells 
are cultured in vitro and ex vivo, and then, (3) injected intravenously into the human body. 
(4) SPIO-labelled SCs are then tracked in the body with MRI. SPIO NPs generate a signal 
that correlates with the cell location and permits non-invasive longitudinal tracking of cell 
therapies.  In  this  example,  MRI  is  used  to  track  SPIO-labelled  cells.  In  the  case  of 
Quantum dots, the same procedure is performed but using fluorescent tracking methods. 
 
Iron oxide NPs are sequestered into SCs through endocytosis during in vitro cell cultivation, and 
accumulate in the endosomes. Depending on the size of them, iron oxide NPs can be internalized by 
several phenomena, including phagocytosis for SPIO and pinocytosis for ultrasmall superparamagnetic 
iron  oxides  particles  (USPIO)  and  magnetodendrimers  micron  sized  iron  oxide  particles  (MPIOs) 
(Figure 3). This process is achieved in non-phagocytic cell types binding uptake-facilitating agents to the 
NP surface. Strategies to improve cell uptake include the use of transfection agents (e.g., poly-L-lysine 
or lipofectamine), electroporation [143], specific targeting and endocytosis of NPs through the use of Int. J. Mol. Sci. 2012, 13 
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transferrin  receptors  [144],  magnetodendrimers  [145],  or  transduction  agents  such  as  HIV-derived 
TAT protein which has been covalently bound to the particle surface to increase the transportation across 
the cell membrane [146–148]. According the cell line used and the NP employed it is important to assess 
specific parameters to achieve a highest uptake rate while not affecting the cell growth and function. 
4.1.2. SPIO: In Vivo Studies 
Different  studies  using animal  models  have been carried out  to  evaluate the use of SPIO as  a 
biomedical  tool.  SPIO  labelling  technique  has  been  successfully  used  to  study  cell  function  and 
integration after transplantation in the cerebral nervous system (CNS), heart, liver, and kidney as well 
as in pancreatic islets of animal models. 
Besides in vivo tracking conditions, SPIO NPs have been used to establish how intravenous delivery 
of human adipose stem cells (h-ADSC) can home to the radiofrequency ablated canine myocardial 
lesion and express a cardiomyocyte-like phenotype [149]. In diabetes mellitus allogeneic transplantation 
followed by MRI monitoring was used for the detection of SPIO-labelled pancreatic islets transplanted 
into the liver. Results showed graft rejection response over a 6-week period after transplantation [150]. 
In a same context, another study demonstrated the harmful effect of hyperglycemia in the survival-rates 
of islets grafts [151]. 
Cell therapies developed to cure neurological disorders such as multiple sclerosis (MS) have used 
SPI-labelled cells for high resolution monitoring of the bio-distribution of cells after transplantation 
into the CNS. Experimental autoimmune encephalomyelitis (EAE) mice were used to examine in vivo 
the functional response of glial-committed neural precursor cells (NPCs) labelled with SPIO. Results 
showed that labelled cells migrated over comparable distances and differentiated into glial lineages in 
the  same  way  as  unlabeled  cells  [152].  NPCs possess  immune-modulating  characteristics  that  are 
neuroprotective [153,154] and it is known that SPIO-labelling does not adversely affect NPC survival 
and differentiation within EAE brain [155,156]. Other in vivo studies have monitored the progression 
of neural SC therapy using NPs for up to 6 weeks [156,157]. A recent study showed that NPCs migrated 
when they were transplanted during either the acute or chronic disease phase and also observed the 
existence of differential NPC migration patterns; an important consideration for implementing future 
translational studies in MS patients with variable disease [158]. 
Although NPs have important applications for tracking SCs, however, there are potential scientific 
issues as well as safety issues that must be considered before clinical trials. In fact, clinical trials are 
hampered  by  basic  research;  nevertheless,  few  clinical  trials  using  NPs  are  recruiting  people  at  
the moment.  
4.2. Quantum Dots (QDs) 
Quantum dots (QDs) are another class of nanomaterials with unique optical features, typically in the 
size range of 2–10 nm. They are inorganic fluorescent semiconductor NPs coated with an outer shell of 
a different material. First studies demonstrated the use of QDs as luminescent cell markers [159,160]. 
Currently, QDs are commercially available offering significant advantages over conventionally used 
fluorescent markers, due to their photostability, which allows long-term cell labelling and in vivo cell 
tracking. QDs are able to maintain fluorescent intensity in cell culture for a prolonged time, up to a few Int. J. Mol. Sci. 2012, 13 
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hours using confocal microscopy [161]. In fact, QDs are approximately 10–20 times brighter than 
fluorescent proteins [162]. Due to their long fluorescence lifetime QDs signal could be separated from 
background autofluorescence in cells or tissues. As well, the narrow emission and broad excitation 
spectrum of QDs allow quantification and simultaneous identification of multiple markers using single 
wavelength activation [159,160]. 
The major potential applications of QDs in regenerative medicine are their use for labelling and 
tracking of implanted SCs. Monitoring the cells in vivo after transplantation is essential for determining 
the efficacy of SC therapy. In a recent study, QDs were used to label ASCs, in combination with 
heparin, and analyzed their behaviour and organ-specific accumulation after having been transplanted 
in a mouse model of acute liver failure [163]. 
QDs could integrate into SCs through passive loading, receptor-mediated endocytosis or transfection. 
Rosen et al. showed that passive loading of QDs resulted in uniform diffused cytoplasmic labelling of 
a population of hMSCs and maintained similar proliferative and differentiation capacities compared to 
unloaded hMSCs. Then, passive loading of QDs in hMSCs is an effective method for uptake and did 
not significantly affect the features of the cells [164]. 
Progress in SC research has prioritized the refinement of cell-labelling techniques. Therefore, for 
effective labelling of MSCs and long observation by QDs in vivo it is necessary both to increase 
cellular uptake of QDs and to promote endosomal escape into the cytosol. In this matter, specific 
peptides such as cholera toxin [165], TAT-peptide [166], octa-arginine peptide phospholipids [167] or 
the polyamidoamine (PAMAM) dendrimer [168] have been used for efficient internalization of QDs. 
In  addition,  QDs  have  the  capacity  to  be  functionalized  by  means  of  cross-linking  with  proteins, 
streptavidin, antibodies, or other bioactive molecules [161,169], which allow QDs to be targeted to 
specific intracellular components and function as cell lineage tracing. 
Different  studies  have  been  carried  in  order  to  analyze  the  effect  of  QDs  on  SCs  properties;  
Slotkin et al. conducted an assay directing QDs labelling of mammalian stem and progenitor cells  
in vivo to study the developing mammalian central nervous system. Ultrasound guided in vivo delivery 
techniques were developed to specifically and efficiently label NSCs and progenitor cells (NSPCs) 
with QDs. QDs were found in the cell types generated by NSPCs at substantial distances away from 
the initial site of injection, suggesting that QD loading of NSPCs in vivo did not inhibit their migration 
or differentiation during the developmental cycle. Therefore, QDs labelling may be particularly useful 
for embryonic studies about the formation of nascent primordial layers [170]. 
QDs are also attractive nanomaterials for monitoring stem cell survival, location, and differentiation 
either in vitro or in vivo due to their inherent long-term fluorescence intensity [165–167]. Stem cells, 
by definition, are capable of self-replication and differentiation into multiple lineages; consequently 
many studies have been executed to show that these cells can be effectively labelled by QDs during 
both proliferation and multilineage differentiation for long term [171–173]. 
In conclusion, QDs based cell labelling can be used as a safe and effective means to facilitate  
in  vivo  trafficking  of  therapeutic  cells.  However,  further  studies  are  necessary  to  demonstrate  the 
outcomes of QDs on long-term effects and their degradation products on SCs. In fact, the release of 
reactive  oxygen  species  during  the  degradation  of  QDs  contributes  to  its  cytotoxicity  [174,175]. 
Although, QDs are not completely innocuous it might be possible to coat the QDs in a way that 
circumvents their in vivo degradation. Int. J. Mol. Sci. 2012, 13 
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5. Functionalized Peptide Nanostructures  
After decades of fine-tuning many biological materials can now be designed and fabricated at the 
molecular level for particular uses. Because of their chemical complexity and structural sophistication, 
biological materials of natural origin have been more difficult to design and fabricate at the molecular 
level. However, over the last two decades the efforts of chemical scientists, chemical engineers, materials 
scientists and medical doctors have borne fruit and now a wide range of biomaterials for medical 
applications exist.  
Peptide nanostructures containing bioactive signals that combine bioactivity for multiple targets 
with biocompatibility, improve the possibility to deliver proteins, nucleic acids, drugs and cells. Their 
chemical design versatility leads to a variety of possible secondary, tertiary and quaternary structures 
through folding and hydrogen bonding. In particular, β-sheet forming peptides have demonstrated the 
extraordinary ability to use intermolecular hydrogen bonding for the assembly of one-dimensional 
nanostructures.  Furthermore,  the  design  of  self-assembly  peptides  for  targeted  functions  can  also 
include their modification with other biomolecular units such as sugars, lipid components and nucleic 
acid monomers. These oligopeptides, whilst designed for supramolecular self-assembly, could also 
serve to functionally mimic large proteins. For these reasons, self-assembling, nonimmunogenic peptides 
project as promising new therapeutics for human disease [176–178]. 
The first self-assembling peptide discovered was the EAK16, also named zuotin protein for its 
ability to bind to left-handed Z-DNA, which contains ubiquitous right-handed B-DNA and other DNA 
structures  [179].  This  peptide  sequence  (N-AEAEAKAKAEAEAKAK-C)  has  been  extensively 
studied to create a class of simple β-sheet peptides [180]. These peptides are ionic self-complementary as 
a result of the presence of both positive and negative side chains on one side of the β-sheet  and 
hydrophobic side chains on the other. These peptides have two distinctive sides, one hydrophobic and 
the other hydrophilic. The hydrophobic side forms a double sheet inside of a fibre and the hydrophilic 
side forms the outside of the nanofibres that interact with water molecules, forming an extremely high 
water content hydrogel, which can contain as high as 99.5% to 99.9% water (1–5 mg peptide per mL 
water,  w/v).  When  dissolved  in  water  in  the  presence  of  salt,  they  spontaneously  assemble  into  
well-ordered nanofibres and, then, further into scaffolds peptides, which form 3D nanofibre scaffolds 
that have been used in 3D cell tissue cultures. 
Since EAK16 was discovered, many peptides and combinations are being studied. These peptide 
amphiphiles (PAs) not only have been used as scaffolds that provide structural support and bioactive 
signals, but these materials have also been moulded to allow for the study of the effects of matrix 
geometry on the behaviour of cells. 
Some examples of different types of peptides that are being investigated and their possible application 
in regenerative medicine are: 
1  The  Ile-Lys-Val-Ala-Val  (IKVAV)  peptide  sequence,  derived  from  laminin,  has  been 
incorporated  into  PAs  for  applications  in  neural  regeneration  to  enhance  neural  attachment, 
migration and neurite outgrowth. Neural progenitor cells cultured in vitro within networks of 
IKVAV PA quickly undergo selective and rapid differentiation into neurons with the formation 
of astrocytes  being largely suppressed  [26]. Control  experiments  using a mixture of soluble 
IKVAV  peptide  and  PA  nanofibres  without  the  IKVAV  epitope  did  not  reveal  this  same Int. J. Mol. Sci. 2012, 13 
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response. These in vitro results suggested that the IKVAV PA may be a useful material in the 
treatment  of spinal  cord injury, where the  formation of a  glial  scar,  comprised primarily of 
astrocytes, prevents axonal regeneration after injury [181]. Mice treated with an injection of 
IKVAV PA solution 24 h after spinal cord injury showed that at the site of injection this solution 
formed nanofibres by self-assembly through electrolyte screening of the molecules. The material 
reduced cell death at the injury site and decreased the astrogliosis involving a hyperplasic state of 
astrocytes. The injected  nanofibre  gel  also increased the number of oligodendroglia, the cells 
responsible for the formation of the myelin sheath around neurons in the central nervous system, 
at the injury site. Histological evidence was also obtained for the regeneration of descending 
motor axons as well as ascending sensory axons across the site of spinal cord injury in animals 
treated with the IKVAV PA [177]. This was accompanied by behavioural improvement in treated 
animals demonstrating enhanced hind limb functionality [182]. 
2  An  interesting  PAs  with  angiogenesis  properties  is  the  heparin-binding  peptide  amphiphile 
(HBPA), which was designed with a Cardin-Weintraub heparin-binding domain to specifically 
bind heparan sulphate-like gylcosaminoglycans (HSGAG). This glycosaminoglycan displayed 
charges on the HBPA molecules, triggering PA self-assembly into nanofibres that presented 
heparin on their surface. Moreover, they were able to capture many potent signalling proteins 
through  their  heparin-binding  domains,  including  fibroblast  growth  factor  2  (FGF-2),  bone 
morphogenetic protein 2 (BMP-2) and vascular endothelial growth factor (VEGF). This material 
was biodegraded and quickly remodeled into a well vascularised connective tissue without the 
addition of any exogenous growth factors [183–185]. 
3  Since nitric oxide has long been recognized as a possible solution to prevent complications of 
neointimal  hyperplasia  during  angioplasty  treatment  in  patients  with  atherosclerosis,  PAs 
presenting heparin were mixed with diazeniumdiolate nitric oxide donors to prepare nitric oxide 
releasing nanofibre gels [186]. When applied to a rat carotid artery balloon injury model, the 
nitric oxide releasing PA nanofibre gels led to a reduction in neointimal hyperplasia by up to 
77% compared with the controls, and also limited inflammation in the injury site [177]. 
4  PA  nanofibres  were  explored  as  a  means  to  functionalize  the  metal  implants  to  enhance 
bioactivity and prompt tissue growth around the implant to assist in long-term implant fixation. 
A nickel-titanium (NiTi) alloy that is frequently used for stents, bone plates, and artificial joints 
was  modified through covalent attachment of PA nanofibres  using standard silanization and 
cross-linking  chemistry  [187,188].  Modifying  the  metal  with  RGDS-epitope  presenting  PAS 
leads to a significant increase in the number of adhered pre-osteoblastic cells cultured in vitro, 
whilst cells did not attach to the non-functionalized NiTi [187]. 
5  Branched RGDS-presenting PA nanofibres have been also used as scaffolds for ameloblast-like 
cells and primary enamel organ epithelial cells that initiate the process of enamel formation. 
When treated with branched RGDS PA nanofibres in vitro, these cells showed an enhancement in 
proliferation  and  increased  their  expression  of  amelogenin  and  ameloblastin,  two  proteins 
secreted by ameloblasts during enamel formation [189]. PAs have been also used in an in vitro 
scaffold  for  dental  SCs,  where  SCs  from  human  exfoliated  deciduous  teeth  proliferate  and 
secrete  a  soft  collagen  matrix  when  encapsulated  within  the  PA,  whilst  dental  pulp  SCs Int. J. Mol. Sci. 2012, 13 
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differentiate into an osteoblast-like phenotype and deposit mineral when encapsulated within the 
gel [190]. 
6  The β-sheet peptide nanostructures have been also evaluated for the treatment of enamel decay, 
resulting in significant gains of net mineral within the lesions over the 5-day study. The peptide 
gels  also  nucleated  the  formation  of  de  novo  hydroxyapatite  when  incubated  in  mineralizing 
solutions [191]. The same peptides were evaluated as an injectable joint lubricant for the treatment 
of osteoarthritis [192]. 
7  Another peptide design that captures the self-assembling potential afforded by the β-sheet was 
prepared from monomers of alternating hydrophilic and hydrophobic residues, lysine and valine, 
respectively, flanking an intermittent tetrapeptide designed to mimic a Type II b-turn, termed a  
β-hairpin peptide. These peptides are designed to be hydrated in pure water, adopting a random 
coil conformation. Studies in vitro have found that these β-hairpin hydrogels can support survival, 
adhesion, and migration of fibroblasts, and can be used to encapsulate MSCs and hepatocytes. 
These gels have also been found to have inherent antimicrobial properties; showing selective 
toxicity to bacterial cells compared with mammalian cells [177,193,194]. 
8  The ionic self-complimentary peptides based on β-sheet-rich proteins from nature, prepared from 
sequences of alternating hydrophobic and hydrophilic residues, have the ability to support cell 
attachment to promote the survival, proliferation, differentiation and neurite growth for neural 
cells.  Moreover,  they  were  capable  to  promote  differentiation  of  liver  progenitor  cells  into 
hepatocyte  spheroids  and  serve  as  scaffolds  for  human  endothelial  cells,  as  well  as  for 
chondrocytes and for osteogenic differentiation of hESCs [177,195–197].  
9  Self-assembling  peptides  can  also  use  conjugated  aromatic  groups  such  as  carbobenzyloxy, 
naphthalene,  or  fluorenylmethyloxycarbonyl  on  the  N-terminal  end  of  di-  and  tri-peptides, 
demonstrating the formation of very stable, highly aunable hydrogels. A number of these sheets  
twist together to form nanotubes. These materials can also support chondrocyte survival and 
proliferation in both 2D and 3D [198,199]. 
Furthermore these systems can be used as templates for nanofabrication and biomineralization of 
synthetic replacements in biological tissues, with specific medical applications including diagnostic 
technologies. Indeed, functionalized peptide nanostructures are part of the immediate future with high 
relevance in regenerative medicine and drug delivery. 
6. Nanoparticles for Gene and Drug Delivery into SCs 
When a drug is introduced in the human body using traditional administration methods, a cascade 
of  biotransformations  occurs  as  result  of  its  interaction  with  the  biological  environment.  These 
processes are part of the drug metabolism. Drug metabolism is very complex and comprises oxidation, 
reduction, hydrolysis and conjugation reactions leading to final excretion from the body. Depending on 
the anatomical route, administered drugs are passing, upon absorption, through several tissues and 
organs (e.g., liver) before reaching the systemic circulation. In those organs, drugs may be subjected to 
chemical or enzymatic degradation. As a result, a higher dose of drug is necessary to ensure relevant 
therapeutic levels. Gene delivery methods using viral vectors, such as retroviruses, adenoviruses, and 
adeno-associated viruses, are extensively used and show superior transfection efficiency [200,201]. Int. J. Mol. Sci. 2012, 13 
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However, viral vectors have shown the disadvantages of potential immunogenicity and carcinogenicity, 
and have a complicated synthesis procedure. In this respect, the application of nanotechnology can be 
an answer toward the discovery and use of efficient and improved drug and gene delivery systems. 
NPs can be used as effective carriers of DNA, RNAi, proteins, peptides and small drugs for stem cell 
differentiation or survival [202]. 
In recent years, SC nanotechnology has emerged as a new exciting field since it overcomes some of 
the major limitations of conventional delivery system [203]. Novel nanomaterials, nanostructures, and 
nanotechnology have emerged to improve gene and drug delivery in SC-based therapies for injuries 
and degenerative diseases [204,205]. The plastic characteristic of nanomaterials implies that can be 
modified in size, morphology and solubility in order to increase cellular uptake. As a result, with the 
use of nanomaterials the pharmacokinetics of drugs can be controlled so that sustained therapeutic 
concentrations can be maintained at specific locations in the body with minimal side effects [206]. 
Non-viral  gene  vectors,  including  liposomes  and  cationic  polymers,  have  received  great  attention 
because  of  their  easy  preparation,  lack  of  immunogenicity,  and  ability  to  be  modified  for  
potential  targeted  delivery  [207,208].  Among  the  cationic  polymers,  polyethylenimine  [209]  and 
polyethylene glycol [210] were reported to be effective transfection reagents due their easy synthesis 
and multiple modifications.  
6.1. Nanoparticles for Drug Delivery into SCs 
Drug delivery systems into stems cells are associated above all with the field of the cancer stem 
cells (CSCs). Carcinogenesis in humans is a multistage process, and the two major stages have been 
designated  initiation  and  promotion.  Although  the  biochemical  basis  for  initiation  and  promotion 
remains to be established, recent research has provided important insights into potentially significant 
biologic mechanisms. Today is known that the initiation of carcinogenesis may result from cellular 
immortalization and the development of defects in the integrated control of stem cell proliferation and 
differentiation  and  that  the  promotion  of  carcinogenesis  may  result  when  such  initiated  SCs  
develop aberrant auto-regulatory growth-control properties. Understanding the role of CSCs during 
carcinogenesis, from tumour initiation to metastasis formation, has become a major focus in stem cell 
biology and in cancer research [211]. Nano-scale delivery systems provide bio-compatible platforms 
which combine the delivery of different therapeutic agents that act synergistically in one single vehicle. 
In addition, these systems can be multi-functionalized with targeting peptides or antibodies, which 
results in the selective targeting of the tumour site and CSCs. So, the drugs specifically reach the 
tumour tissues in the correct ratios and, thus, lower doses are expected to be required, which would 
reduce the number and severity of putative side effects. Eventually, multifunctional systems combined 
with CSC-targeting therapies should allow the specific and efficient delivery to tumour tissue, spare 
normal tissue and SCs, and result in the elimination of tumour cells, including stromal cells and CSCs.  
In  the  past  decade,  NP-based  drug  delivery  systems  have  shown  exciting  efficacy  for  cancer 
treatments  due  to  their  improved  pharmacokinetics  and  biodistribution  profiles  via  the  enhanced 
permeability and retention (EPR) effect. Efficient delivery of therapeutics into tumour SCs to increase 
the intracellular drug concentration is a major challenge for cancer therapy due to drug resistance  
and inefficient cellular uptake. In this context, Du et al. designed a tailor-made dual pH-sensitive  Int. J. Mol. Sci. 2012, 13 
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polymer-doxorubicin conjugate nanoparticulate system to overcome the challenges. The NP is capable 
of reversing its surface charge from negative to positive at tumour extracellular pH (± 6.8) to facilitate 
cell internalization. Subsequently, the significantly increased acidity in subcellular compartments such 
as the endosome (± 5.0) further promotes doxorubicin release from the endocytosed drug carriers. This 
dual pH-sensitive NP has shown enhanced cytotoxicity in drug-resistant cancer SCs, indicating its 
great potential for cancer therapy [212].  
In addition, the combination of SCs and drug-loaded NPs for therapeutic applications in glioma 
therapy is a promising strategy, as NP could protect therapeutic agent and could allow its sustained 
release. The prognosis of patients with malignant glioma remains extremely poor, despite surgery and 
improvements  in  radio-  and  chemotherapies.  However,  new  paradigms  allowing  tumour  specific 
targeting and extensive intratumoral distribution must be developed to efficiently deliver NPs. Taking 
advantage into the fact that MSCs have a natural tropism toward brain tumours, Roger et al. proved 
that these cells could be used as NP delivery vehicles [213]. Two types of NPs loaded with coumarin-6 
were  investigated:  (i)  PLA-NPs  and  (ii)  lipid  nanocapsules  (LNCs).  Adult  human  marrow  SCs 
efficiently  internalized  coumarin-6-PLA-NPs  and  coumarin-6-LNCs  in  a  concentration  and  time-
dependent manner. Moreover, cell viability and differentiation were not affected. Furthermore, these 
NP-loaded cells were able to migrate and distribute around the tumor mass by using the U87MG 
experimental human glioma in nude mice. These data suggest that MSCs can serve as cellular carriers 
for  NPs  in  brain  tumours  and  represent  a  promising  tool  as  cell  delivery  systems  in  brain  tumor  
therapy [213,214].  
Low  targeting  efficiency  is  one  of  the  biggest  limitations  for  NPs  drug  delivery  system-based 
cancer therapy. In another study MSCs were used as targeting vehicle and a silica nanorattle was 
employed  as  drug  carrier  [215,216].  The  silica  nanorattle-doxorubicin  drug  delivery  system  was 
efficiently  anchored  to  the  MSCs  by  specific  antibody-antigen  recognitions  at  the  cytomembrane 
interface without any cell preconditioning. Up to 1500 NPs were uploaded to each MSC with high cell 
viability and tumour-tropic ability [217]. In vivo experiments proved that the burdened MSCs could 
track  down  the  U251  glioma  tumour  cells  more  efficiently  and  deliver  doxorubicin  with  wider 
distribution and longer retention lifetime in tumour tissues compared with free doxorubicin and silica 
nanorattle-encapsulated  doxorubicin.  The  increased  and  prolonged  doxorubicin  intratumoral 
distribution  further  contributed  to  significantly  enhanced  tumour-cell  apoptosis.  This  strategy  has 
potential to be developed as a robust method for targeted tumour therapy with high efficiency and low 
systematic toxicity [217]. 
6.2. Nanoparticles for Gene Delivery into SCs 
Tissue engineering can generally be divided into three main methodological areas of interest: direct 
gene  delivery,  cell  therapy  without  involving  genetic  modification,  and  genetically  modified  
cell-mediated therapy. The direct approach, gene delivery, focuses on an in vivo therapeutic transfer of 
genes to the host’s cells. These genes affect the host tissue in situ and induce tissue formation [218] 
and regeneration [219]. Cell therapy focuses on the use of naive cells mostly obtained from stem  
cell  populations,  which  are  placed  in  the  site  of  injury  with  the  goal  of  enhancing  tissue  
regeneration  [220,221].  Genetically  engineered  cell  therapy  employs  both  techniques:  using  Int. J. Mol. Sci. 2012, 13 
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tissue-specific or therapeutic genes and primary cells that overexpress these genes, it is possible to 
produce  therapeutic  proteins  at  sites  of  regeneration  or  to  differentiate  new  cells  into  the  desired 
cellular lineage and thus promote tissue regeneration [222]. Gene-modified MSCs possess superior 
characteristics of specific tissue differentiation [223], resistance to apoptosis [224], and directional 
migration [225]. Thus, nanotechnology is a useful tool for both generation and differentiation of SCs. 
6.2.1. Nanoparticle for Generation of Induced Pluripotent SCs 
Reprogramming human somatic cells to induce pluripotent stem cells (iPSCs) by defined transcription 
factors (Oct3⁄4, Sox2, Klf4 and c-Myc) [226] has revolutionized the stem cell research community. 
iPSCs, like ESCs, have the potentiality to differentiate into any type of cell in the body but could be 
derived from patients’ own cells and therefore, transplantation may not require immunosuppressive 
therapy [227]. In addition, iPSCs research obviates the political and ethical dilemma associated with 
embryo destruction and ESC research. This remarkable discovery of cellular plasticity has important 
medical implications. iPSCs have great potential in human regenerative medicine and seem to be a 
good option in the treatment of several diseases, such as Parkinson's, macular degeneration or Type I 
diabetes, that require a homogenous population of mature and terminally differentiated cells.  
Figure  4.  Generation  of  iPSCs  from  mouse  embryonic  fibroblasts  by  magnet-based 
nanofection. Plasmid DNAs containing reprogramming factors (Oct3⁄4, Sox2, Klf4 and  
c-Myc) were mixed with magnetic NP and the complexes were added to dishes that were 
applied to a magnetic field.  
 
Although iPSCs offer great possibilities, there is a crescent concern regarding the procedures used 
to induce the pluripotentiality. The main techniques imply the use of viral vectors, such as retrovirus 
and lentivirus, which integrate the reprogramming factors into the host genomes and may increase the 
risk of tumour formation. Several non-integration methods have been reported to overcome the safety 
concern associated with the generation of iPSCs, such as transient expression of the reprogramming 
factors using adenovirus vectors or plasmids, and direct delivery of reprogramming proteins. Although 
these transient expression methods could avoid genomic alteration of iPSCs, they are inefficient [228]. Int. J. Mol. Sci. 2012, 13 
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The application of nanotechnology in iPSCs generation has attractive technological prospects; however, 
so far, few reports are closely associated with the use of nanotechnology to enhance the derivation of 
human iPSCs and labelling iPSCs cells for long-term tracking of their in vivo distribution. In this 
context,  recently  Lee  and  collaborators  [229]  generated  iPSCs  from  fibroblasts  using  a  non-viral 
magnetic  NP-based  transfection  method  that  employs  biodegradable  cationic  polymer  PEI-coated 
super  paramagnetic  NP.  These  findings  support  the  possible  use  of  magnet-based  nanofection  for 
transient expression of transcription factors in somatic cells for efficient generation of iPSCs (Figure 4). 
After transfection, nanofection-mediated iPSCs showed ESC-like characteristics, including expression 
of  endogenous  pluripotency  genes,  differentiation  of  three  germ  layer  lineages,  and  formation  of 
teratomas. These results demonstrate that magnet-based nanofection may provide a safe method for use 
in generation of virus-free and exogenous DNA-free iPSCs, which will be crucial for future clinical 
applications in the field of regenerative medicine. Furthermore, Ruan et al. [230] successfully used 
fluorescent magnetic NPs (FMNPs) to label iPSCs for long-term observation and tracking.  
6.2.2. Nanoparticle as a Delivery System for SCs Differentiation  
The  ability  to  deliver  biomolecules  via  an  intracellular  route,  including  growth  factors,  genes, 
proteins, and small chemicals, presents an excellent tool to direct SCs differentiation into specific cell 
types as bone, cartilage, muscle, adipose and cardiac. Some of these biomolecules/chemicals (i) have 
poor  solubility,  (ii)  can  be  quickly  cleaved  by  cellular  enzymes,  and  (iii)  have  side  effects  when 
administered systemically. Biodegradable and biocompatible NPs able to target SCs and release the 
payload in their cytoplasm, with consequent activation of signalling cascades, will be of great interest.  
Growth  factors  are  naturally  occurring  proteins  capable  of  stimulating  cellular  proliferation, 
migration  and/or  differentiation  into  a  specialized  phenotype.  Because  they  are  involved  in  the 
regulation of several cellular functions, they can enhance the healing and regeneration processes of 
diverse tissues [231]. Nowadays, numerous growth factors are being identified, some of which produced 
by recombinant technology [232]. Due to the limited half-lives of many of these proteins in vivo, they 
are difficult to administer to sites of damaged tissue at therapeutic concentrations and for sustained 
periods of time. Thus, the way these molecules should be delivered to the injury site plays a crucial 
role for their success as therapeutic agents. To overcome the limitations of traditional methods of 
administration, several technologies using biomaterials have been explored to achieve a better control 
over the growth factor release. In this context, recently was reported a new approach for the delivery of 
vascular  growth  factors  into  hESCs,  by  incorporating  growth  factor-release  particles  in  human 
embryoid bodies (EBs)  [202]. The incorporation of these polymeric biodegradable particles had a 
minimal effect on cell viability and proliferation but a large impact on differentiation. The effect on 
vascular differentiation of particles containing growth factors was superior to the one observed by 
exposing EBs to large extrinsic doses of the same growth factors. These NPs could serve as a platform 
to deliver growth factors and other biomolecules within SCs (Figure 5). Int. J. Mol. Sci. 2012, 13 
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Figure 5. Growth factor-release based on a biomaterial approach to deliver signals to cells 
towards their differentiation for applications in tissue regeneration. 
 
Moreover, use of NPs, as delivery system, could be the best choice for bone regeneration, as there is 
no need for long-term overexpression of bone morphogenetic proteins (BMP) to induce valid bone 
formation. Transient overexpression of protein for a few weeks is sufficient to initiate the regeneration 
process. Indeed, many studies have shown the potential for MSCs that transiently overexpress BMP to 
induce  bone  formation  on  nanofibres  [233]  and  chitosan-coated  BMP-2  NPs  [234].  Furthermore, 
several types of NPs were used as a delivery system to induce cartilage regeneration. Thus, for the safe 
and stable delivery of genes and to induce chondrogenesis, biodegradable PLGA NPs were used to 
mediate SOX9 gene delivery in hMSCs [235]. In addition, Park et al. [236] employed polycationic 
polymer, PEI polyplexed with a combination of SOX5, 6, and 9 fused to fluorescent protein coated 
onto PLGA NPs. SOX trio complexed with PEI-modified PLGA NPs led to a dramatic increase of 
hMSCs chondrogenesis in vitro culture systems. Recently, in the field of adipogenesis a systematic 
study in rat mesenchymal stem cells (RMSC) demonstrated that the biocompatible silica NP-insulin 
(SiNP) conjugates induce in vitro adipogenic differentiation [237]. Moreover, the biological activity of 
insulin  conjugated  to  the  SiNPs  was  not  affected  and  the  SiNPs  could  be  used  as  biocompatible 
carriers of insulin for RMSC adipogenic differentiation, which would help to expand the new potential 
application  of  SiNPs  in  stem  cell  research.  In  addition,  Yang  et  al.  [238]  achieved  an  efficient 
adipogenic differentiation of hMSC, in vitro as well of in vivo transplanted cells, using the adipogenic 
transcription factors C/EBP-α and C/EBP-β complexed with PEI coupled with biodegradable PLGA 
nanospheres. The expression of specific adipogenic genes and proteins in hMSCs was significantly 
elevated compared to the controls.  
7. Toxicity Issues, Advantages and Limitations 
The use of NPs in biomedical research implies a detailed consideration of their toxicity [239]. Thus, 
a  full  characterization  of  size,  shape,  charge,  surface  chemistry  and  material  properties  must  be Int. J. Mol. Sci. 2012, 13 
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performed as it influences the production of free radicals and subsequent oxidative stress, inducing 
toxicity  [240].  Nanomaterials  may  agglomerate  in  vitro  or  in  vivo  and  may  chemically  degrade, 
making it difficult to relate systematically nanoparticle toxicity to such a diverse set of materials [241]. 
Several  authors point out  that in vitro and in  vivo mechanisms of toxicity depend on the type of  
NPs [240,242,243]. For instance, toxicity of magnetic NPs might be due to several factors such as 
concentration, hydrodynamic size, surface charge, type of coatings, administration route or generation 
of  iron-catalyzed  reactive  oxygen  species.  Evaluation  of  SPIO  cytotoxicity  in  hMSCs  [244,245], 
mESCs [246], and NSCs [247] showed in most cases that the internalization of these NPs by SCs did 
not affect cell viability, growth, or differentiation. Well characterized SPIO-labelled SCs showed a 
promising effect when combined with MRI; however, studies also demonstrate that this particles can  
in fact be transferred from SCs to non-SCs, such as macrophages like kuppfer cells in the liver [248].  
In  conclusion,  more  studies  have  to  be  performed  to  determine  the  cytotoxicity  of  NPs  using 
appropriately validated analytical methods and well designed experimentation, so that nanomaterials 
can safely be used as therapeutics and diagnostic tools. 
8. Conclusions  
Significant advances achieved in both regenerative medicine and nanomedicine offer the promise of 
tissue and organ specific regenerative treatments. The development of functionalized bioactive scaffolds 
and NPs that promote cell proliferation, migration and differentiation  has opened expectations for 
clinical application. However, some questions about safety and effectiveness of SC-based therapy and 
nanomaterials need to be addressed for widespread diagnostic and therapeutic use. A deep understanding 
of  biological  mechanisms  responsible  of  regenerative  processes  based  on  nanomaterials-SC  cell 
therapy is needed to obtain valuable information concerning cell behaviour, efficacy and undesirable 
effects of nanomaterials. Functionalization at molecular level of bioactive and biodegradable nanoscale 
filaments that mimic ECM must be explored in animal models before translation to clinic. After that, 
we  believe  clinical  trials  with  current  and  novel  nanomaterials  will  revolutionize  application  of 
regenerative medicine in patients. 
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